Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels to predict efficacy of bevacizumab in metastatic colorectal cancer patients receiving first-line chemotherapy.

Mitsukuni Suenaga,Shu Cao,Wu Zhang,Yan Ning,Satoshi Okazaki,Martin D. Berger,Yuji Miyamoto,Marta Schirripa,Roel Gopez,Elizabeth Melendez,Shivani Soni,Afsaneh Barzi,Toshiharu Yamaguchi,Heinz-Josef Lenz

Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels to predict efficacy of bevacizumab in metastatic colorectal cancer patients receiving first-line chemotherapy.

2017

Mitsukuni Suenaga
Shu Cao
Wu Zhang
Yan Ning
Satoshi Okazaki
Martin D. Berger
Yuji Miyamoto
Marta Schirripa
Roel Gopez
Elizabeth Melendez
Shivani Soni
Afsaneh Barzi
Toshiharu Yamaguchi
Heinz-Josef Lenz

11564Background: Early VEGF-A reduction by targeting abundant VEGF-A is a potential predictive marker of bevacizumab (BV). CCL5/CCR5 axis modulates VEGF-A production via endothelial progenitor cell...

Keywords:

Bevacizumab
Cancer research
CCL5
Colorectal cancer
VEGF receptors
Pathology
Medicine
Chemotherapy
Predictive marker
Gene
genetic variants
Endothelial progenitor cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations